Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

109.41USD
15 Dec 2017
Change (% chg)

$1.17 (+1.08%)
Prev Close
$108.24
Open
$109.28
Day's High
$109.64
Day's Low
$107.68
Volume
10,411,486
Avg. Vol
6,293,555
52-wk High
$147.17
52-wk Low
$94.55

Latest Key Developments (Source: Significant Developments)

Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA
Thursday, 16 Nov 2017 08:30am EST 

Nov 16 (Reuters) - Celgene Corp :Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA and prime eligibility from EMA for relapsed and refractory multiple myeloma.Celgene Corp - ‍designations based on preliminary clinical data from ongoing phase i study of bb2121 in heavily pre-treated multiple myeloma​.Celgene Corp - ‍updated data from CRB-401 is scheduled to be presented at 59(th) annual meeting of american society of hematology in Atlanta​.  Full Article

Celgene prices $3 billion of senior unsecured notes
Wednesday, 1 Nov 2017 07:30am EDT 

Nov 1 (Reuters) - Celgene Corp :Celgene prices $3 billion of senior unsecured notes.Celgene Corp - ‍announced pricing of three series of senior unsecured notes for aggregate principal amount of $3,000 million​.  Full Article

Celgene announces offering of senior unsecured notes
Tuesday, 31 Oct 2017 09:00am EDT 

Oct 31 (Reuters) - Celgene Corp :Celgene announces offering of senior unsecured notes.Celgene-To use proceeds for repayment of $1 billion outstanding 2.125% senior notes & $400 million outstanding 2.300% senior notes, each maturing Aug 2018​.  Full Article

Lannett and Celgene enter into settlement and license agreement related to Thalomid
Monday, 30 Oct 2017 06:52am EDT 

Oct 30 (Reuters) - Celgene Corp :Lannett and Celgene enter into settlement and license agreement related to Thalomid.Lannett - ‍subject to FDA approval of co's ANDA for thalidomide, co intends to launch product under terms of license agreement, which are confidential​.Lannett-‍license agreement permits co to manufacture, market in U.S. generic thalidomide product as of Aug 1, 2019 or earlier under certain circumstances​.  Full Article

Celgene Corp updates on court order at request of Canadian Competition Bureau - SEC filing
Thursday, 26 Oct 2017 04:52pm EDT 

Oct 26 (Reuters) - Celgene Corp :Celgene Corp says ‍​in Aug, co received an order issued by the Federal Court in Ottawa, Ontario, Canada at request of Canadian Competition Bureau.Celgene Corp - Order requires that co provide certain materials and information relating to co's risk management program.Celgene Corp - Order also requires that co provide requests by generic manufacturers to purchase Celgene's products in Canada.Celgene Corp says it is cooperating with the request of the Canadian Competition Bureau.  Full Article

Celgene initiating share repurchase plan
Thursday, 26 Oct 2017 10:21am EDT 

Oct 26 (Reuters) - Celgene Corp :Celgene CFO says initiating share repurchase plan beginning immediately.  Full Article

Celgene reports Q3 earnings per share of $1.21
Thursday, 26 Oct 2017 07:30am EDT 

Oct 26 (Reuters) - Celgene Corp :Celgene reports third quarter 2017 operating and financial results.Q3 revenue $3.287 billion versus I/B/E/S view $3.42 billion.Q3 earnings per share $1.21.Q3 earnings per share view $1.87 -- Thomson Reuters I/B/E/S.Celgene Corp - ‍updating 2017 guidance and financial targets for 2020​.Celgene Corp - qtrly ‍revlimid sales for Q3 increased 10 percent to $2,081 million​.Celgene Corp - sees ‍2017 GAAP diluted EPS $4.78 to $5.19​.Celgene Corp - qtrly ‍ Abraxane sales for Q3 were $251 million, an 8 percent increase year-over-year​.Celgene Corp - sees 2017‍ adjusted diluted EPS $7.30 to $7.35​.Celgene Corp sees ‍2017 total revenue approximately $13.0 billion​.Celgene Corp - qtrly ‍ Otezla sales for Q3 were $308 million, a 12 percent increase year-over-year​.Celgene Corp - sees ‍ 2017 GAAP operating margin approximately 37.5%​.Fy2017 earnings per share view $7.31, revenue view $13.23 billion -- Thomson Reuters I/B/E/S.Celgene Corp sees ‍2017 Otezla sales approximately $1.25 billion​.Celgene Corp qtrly adjusted EPS ‍$1.91​.  Full Article

Celgene says net pre-tax charge to Q4 earnings estimated to be $300 mln to $500 mln
Thursday, 19 Oct 2017 05:36pm EDT 

Oct 19 (Reuters) - Celgene Corp ::Celgene - concluded oct 18 will recognize q4 charge to earnings related to impairment of about $1,600 million ged-0301 IPR&D asset - sec filing.Celgene - concluded oct 18 will recognize q4 charge to earnings also related to wind-down costs related to discontinuing the trials.Celgene says net pre-tax charge to q4 earnings estimated to be $300 million to $500 million, or $0.27 to $0.45/share after tax regarding discontinuation of trials.  Full Article

Celgene provides update on GED-0301 (mongersen) inflammatory bowel disease program
Thursday, 19 Oct 2017 04:30pm EDT 

Oct 20 (Reuters) - Celgene Corp :Celgene provides update on GED-0301 (mongersen) inflammatory bowel disease program.Celgene Corp - ‍GED-0301 (mongersen) phase iii revolve trial (cd-002) in Crohn's Disease (CD) and extension trial (sustain, CD-004) will discontinue​.Celgene Corp - ‍at this time, phase iii define trial (CD-003) in Crohn's Disease will not be initiated​.Celgene Corp - Celgene has decided to stop trials for GED-0301 following an October recommendation of data monitoring committee ​.Celgene Corp - co waiting to review full dataset from phase ii trial with GED-0301 in Ulcerative Colitis (UC) to determine next steps​.  Full Article

Celgene and Nimbus Therapeutics enter long-term strategic immunology alliance to develop programs for patients with autoimmune disorders
Tuesday, 3 Oct 2017 07:30am EDT 

Oct 3 (Reuters) - Celgene Corp : :Nimbus therapeutics and Celgene enter long-term strategic immunology alliance to develop programs for patients with autoimmune disorders.Celgene Corp - ‍financial terms will remain undisclosed until Celgene acquires a program​.Celgene Corp - ‍Celgene will receive an option to acquire each program in alliance up through a clinical inflection point​.Celgene Corp - ‍Nimbus will receive an upfront payment and potential downstream milestone payments for each program celgene chooses to acquire​.Celgene Corp - ‍Nimbus will retain full control of research and development activities for each program prior to program's option point​.  Full Article

US STOCKS-Wall St ends higher with help from tech, energy

* Cryptocurrency related stocks bounce after bitcoin futures debut